Form 4: Revolution Medicines Director Elizabeth Anderson Reports Acquisition of Shares and Stock Options

Director Elizabeth Anderson reports acquiring shares and stock options in Revolution Medicines, Inc.

Summary

• Elizabeth Anderson, a director of Revolution Medicines, Inc. (RVMD), filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
• On June 20, 2024, Anderson acquired 4,800 shares of common stock and 16,700 stock options.
• The stock options have an exercise price of $37.54 and expire on June 19, 2034.
• The shares subject to the option vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider.
• Following these transactions, Anderson directly owns 20,625 shares of common stock and 16,700 stock options.
• She also indirectly owns 26,990 shares of common stock through the David W. Anderson 1996 Irrevocable Trust.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting insider transactions. The acquisition of shares and options by a director could be interpreted as a mildly positive signal, suggesting confidence in the company's prospects, but it's a routine filing.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Monitoring such filings can provide insights into management's sentiment and confidence in the company's performance.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies like Revolution Medicines.
• Comparing the size and frequency of these transactions to those of directors at comparable biotech firms (e.g., Amgen, Gilead, Biogen) can provide context on the significance of this activity.
• The vesting schedule and exercise price of the stock options are typical for executive compensation packages in the biotech industry.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive sign.
• The transactions themselves have no direct impact on employees, customers, suppliers, or creditors.

Key Dates